Eikon Therapeutics, Inc. Common Stock (EIKN) - Total Liabilities
Based on the latest financial reports, Eikon Therapeutics, Inc. Common Stock (EIKN) has total liabilities worth $313.07 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See EIKN defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Eikon Therapeutics, Inc. Common Stock - Total Liabilities Trend (2023–2025)
This chart illustrates how Eikon Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check Eikon Therapeutics, Inc. Common Stock liquidity resilience to evaluate the company's liquid asset resilience ratio.
Eikon Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Eikon Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ashiana Housing Limited
NSE:ASHIANA
|
India | Rs36.96 Billion |
|
Rieter Holding AG
SW:RIEN
|
Switzerland | CHF1.94 Billion |
|
Wuhu Fuchun Dye and Weave Co.Ltd.
SHG:605189
|
China | CN¥3.28 Billion |
|
Guangdong PAK Corporation Co Ltd
SHE:300625
|
China | CN¥896.13 Million |
|
KINX Inc
KQ:093320
|
Korea | ₩93.85 Billion |
|
ARTS Group Co Ltd
SHG:603017
|
China | CN¥1.89 Billion |
|
Dayang Enterprise Holdings Bhd
KLSE:5141
|
Malaysia | RM292.78 Million |
|
Smcp SAS
PA:SMCP
|
France | €978.00 Million |
Liability Composition Analysis (2023–2025)
This chart breaks down Eikon Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Eikon Therapeutics, Inc. Common Stock assets under control.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eikon Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eikon Therapeutics, Inc. Common Stock (2023–2025)
The table below shows the annual total liabilities of Eikon Therapeutics, Inc. Common Stock from 2023 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.47 Billion | +38.62% |
| 2024-12-31 | $1.06 Billion | +22.62% |
| 2023-12-31 | $867.08 Million | -- |
About Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and… Read more